![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
|
% Change
|
|
|
||||||
Revenue type
|
|
$m
|
Actual
|
CER
|
|
|
|||
Product Sales
|
|
10,566
|
(4)
|
1
|
|
∗ Decline of 4% (1% increase at
CER) impacted by lower sales of COVID-19 medicines
∗ Strong growth in Oncology, CVRM, R&I and Rare
Disease
|
|||
Alliance Revenue
|
|
286
|
88
|
90
|
|
∗ $220m for Enhertu (Q1 2022: $76m)
∗ $43m for Tezspire (Q1 2022: $3m)
∗ See Table 6 for further
details
|
|||
Collaboration Revenue
|
|
27
|
(89)
|
(89)
|
|
∗ No sales or regulatory milestones
from Lynparza in the quarter (Q1 2022:
$175m)
∗ See Table 7 for further
details
|
|||
Total Revenue
|
|
10,879
|
(4)
|
--
|
|
∗ Excluding COVID-19
medicines, Q1 2023
Total Revenue increased by 10% (15% at CER)
|
|||
Therapy areas
|
|
$m
|
Actual %
|
CER %
|
|
|
|||
Oncology
|
|
4,148
|
14
|
19
|
|
∗ Strong performance across key medicines and
regions
∗ No sales or regulatory milestones
from Lynparza in the quarter (Q1 2022:
$175m)
|
|||
CVRM6
|
|
2,557
|
15
|
22
|
|
∗ Farxiga up
32% (39% CER), Lokelma up 56% (64% at CER), roxadustat up 52% (66%
CER), Brilinta up 3% (5% at CER)
|
|||
R&I
|
|
1,633
|
3
|
8
|
|
∗ Fasenra up
10% (13% CER), Breztri up
67% (73% CER). Saphnelo and Tezspire continue to grow rapidly during their launch
phase
∗ Collaboration Revenue of $nil (Q1 2022: $70m,
relating to tralokinumab milestone)
|
|||
V&I[17]
|
|
355
|
(80)
|
(79)
|
|
∗ $127m from COVID-19 mAbs (Q1 2022:
$469m)
∗ $28m from Vaxzevria (Q1 2022: $1,145m)
|
|||
Rare Disease6
|
|
1,866
|
10
|
14
|
|
∗ Ultomiris up
55% (61% at CER), offset by decline in Soliris of 16% (13% at CER)
∗ Strensiq up
26% (28% at CER) reflecting strong patient demand and geographic
expansion
|
|||
Other Medicines
|
|
320
|
(26)
|
(21)
|
|
|
|||
Total Revenue
|
|
10,879
|
(4)
|
-
|
|
|
|||
Regions inc. COVID-19
|
|
$m
|
Actual %
|
CER %
|
|
|
|||
US
|
|
4,299
|
4
|
4
|
|
|
|||
Emerging Markets
|
|
3,162
|
(6)
|
1
|
|
∗ Growth rate impacted by lower sales of COVID-19
medicines (numbers ex. COVID-19 below)
|
|||
- China
|
|
1,602
|
(1)
|
8
|
|
|
|||
- Ex-China Emerging Markets
|
|
1,560
|
(10)
|
(6)
|
|
|
|||
Europe
|
|
2,162
|
(5)
|
-
|
|
|
|||
Established RoW
|
|
1,256
|
(22)
|
(12)
|
|
|
|||
Total Revenue inc. COVID-19
|
|
10,879
|
(4)
|
-
|
|
|
|||
Regions ex. COVID-19
|
|
$m
|
Actual %
|
CER %
|
|
|
|||
US
|
|
4,299
|
15
|
15
|
|
|
|||
Emerging Markets
|
|
3,136
|
14
|
22
|
|
|
|||
- China
|
|
1,602
|
2
|
11
|
|
∗ Third consecutive quarter of growth at
CER
∗ Recovery in inhaled products following lifting of
COVID-19 restrictions
|
|||
- Ex-China Emerging Markets
|
|
1,534
|
31
|
38
|
|
∗ Timing of Rare Disease tender
orders
|
|||
Europe
|
|
2,148
|
3
|
9
|
|
|
|||
Established RoW
|
|
1,142
|
(5)
|
7
|
|
|
|||
Total Revenue ex. COVID-19
|
|
10,725
|
10
|
15
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
Metric
|
Reported
|
Reported change
|
Core
|
Corechange
|
|
Comments[18]
|
Total Revenue
|
$10,879m
|
-4% Actual stable at CER
|
$10,879m
|
-4% Actual stable at CER
|
|
∗ Excluding COVID-19 medicines, Q1 2023 Total
Revenue increased by 10% (15% at CER)
∗ See Table 1 and the Total Revenue section of this
document for further details
|
Gross Margin[19]
|
82%
|
14pp Actual 14pp CER
|
83%
|
4pp Actual 4pp CER
|
|
+
Increasing mix of sales from Oncology and Rare Disease
medicines
+ Decreasing mix of Vaxzevria sales
‒ Increasing
mix of products with profit-sharing
arrangements
∗ Variations in Gross Margin can
be expected between periods due to product seasonality, foreign
exchange fluctuations, cost inflation and other
effects
|
R&D expense
|
$2,611m
|
22% Actual 28% CER
|
$2,300m
|
5% Actual 10% CER
|
|
+
Increased investment in the pipeline
+
Reported R&D expense was also impacted by intangible asset
impairments in Q1 2023, and by reversals of impairments in Q1
2022
∗ Core R&D-to-Total Revenue ratio of 21%(Q1
2022: 19%)
∗ Year-on-year comparisons can be impacted by
differences in cost phasing
|
SG&A expense
|
$4,059m
|
-16% Actual -13% CER
|
$3,054m
|
4% Actual 8% CER
|
|
+
Market development activities for recent launches
+
Core SG&A-to-Total Revenue ratio of 28%(Q1 2022:
26%).
‒ Reported
SG&A in Q1 2022 included a $775m charge for a legal settlement
with Chugai Pharmaceutical Co. Ltd
∗ Year-on-year comparisons can be impacted by
differences in cost phasing
|
Other operating income[20]
|
$379m
|
>3x Actual >3x CER
|
$318m
|
>3x Actual >3x CER
|
|
∗ Reported and Core OOI includes a gain of $241m
from the disposal of US rights to Pulmicort
Flexhaler
|
Operating Margin
|
23%
|
16pp Actual 16pp CER
|
36%
|
2pp Actual 1pp CER
|
|
∗ See Gross Margin, Expenses and OOIcommentary
above
|
Net finance expense
|
$287m
|
-10% Actual -8% CER
|
$240m
|
-4% Actual -3% CER
|
|
∗ Higher interest received on cash balances,
partially offset by higher rates on floating debt and bond
issuances
∗ Reported also impacted by a reduction in the
discount unwind on acquisition-related
liabilities
|
Tax rate
|
20%
|
-10pp Actual -10pp CER
|
20%
|
-1pp Actual -1pp CER
|
|
∗ Variations in the tax rate can be expected between
periods
|
EPS
|
$1.16
|
>4x Actual >4x CER
|
$1.92
|
1% Actual 6% CER
|
|
∗ Further details of differences between Reported
and Core are shown in Table 13
|
Event
|
Medicine
|
Indication / Trial
|
Event
|
Regulatory approvals and other regulatory actions
|
Imfinzi +/- Imjudo
|
NSCLC (1st-line) (POSEIDON)
|
Regulatory approval (EU)
|
Imfinzi + Imjudo
|
Hepatocellular carcinoma (1st-line) (HIMALAYA)
|
Regulatory approval (EU)
|
|
Enhertu
|
HER2-positive breast cancer (2nd-line)
(DESTINY-Breast03)
|
Regulatory approval (CN)
|
|
Calquence
|
Maleate tablet formulation
|
Regulatory approval (EU)
|
|
Calquence
|
Mantle cell lymphoma
|
Regulatory approval (CN)
|
|
Ultomiris
|
NMOSD
|
Positive CHMP opinion (EU)
|
|
Regulatory submissionsor acceptances
|
Imfinzi
|
Biliary tract cancer (TOPAZ-1)
|
Regulatory submission (CN)
|
Enhertu
|
HER2+ breast cancer (3rd-line) (DESTINY-Breast02)
|
Regulatory submission (EU)
|
|
Beyfortus
|
RSV[21] (MELODY/MEDLEY)
|
Regulatory submission (JP)
|
|
eplontersen
|
ATTRv-PN[22] (NEURO-TTRansform)
|
Regulatory submission (US)
|
|
|
danicopan
|
PNH with EVH
|
Regulatory submission (EU)
|
Major Phase III data readouts and other developments
|
Lynparza + Imfinzi
|
Ovarian cancer (1st-line) (DUO-O)
|
Primary endpoint met
|
Imfinzi
|
NSCLC (neoadjuvant) (AEGEAN)
|
Dual primary endpoints met
|
Medicine
|
Trial name
|
Indication
|
datopotamab deruxtecan
|
AVANZAR
|
NSCLC (1st-line)
|
TROPION-Lung07
|
Non-squamous NSCLC (1st-line)
|
|
camizestrant
|
CAMBRIA-1
|
HR-positive[23]/HER2-negative
adjuvant breast cancer
|
Tezspire
|
CROSSING
|
Eosinophilic oesophagitis
|
AZD3152
|
SUPERNOVA
|
COVID-19 prophylaxis
|
Ultomiris
|
ARTEMIS
|
Cardiac surgery associated acute kidney injury
|
|
Q1 2023
|
|
||||||
|
|
|
% Change
|
|
||||
Product Sales
|
|
$m
|
% Total
|
Actual
|
CER
|
|||
Oncology
|
|
3,920
|
36
|
16
|
21
|
|||
- Tagrisso
|
|
1,424
|
13
|
9
|
15
|
|||
- Imfinzi [25]
|
|
900
|
8
|
50
|
56
|
|||
- Lynparza
|
|
651
|
6
|
5
|
10
|
|||
- Calquence
|
|
532
|
5
|
28
|
31
|
|||
- Enhertu
|
|
37
|
-
|
>3x
|
>3x
|
|||
- Orpathys
|
|
8
|
-
|
(33)
|
(27)
|
|||
- Zoladex
|
|
227
|
2
|
(6)
|
3
|
|||
- Faslodex
|
|
75
|
1
|
(19)
|
(11)
|
|||
-
Others
|
|
66
|
1
|
(32)
|
(27)
|
|||
BioPharmaceuticals: CVRM
|
|
2,530
|
23
|
15
|
21
|
|||
- Farxiga
|
|
1,299
|
12
|
30
|
37
|
|||
- Brilinta
|
|
334
|
3
|
3
|
5
|
|||
- Lokelma
|
|
98
|
1
|
56
|
64
|
|||
-
roxadustat
|
|
61
|
1
|
49
|
63
|
|||
- Andexxa
|
|
44
|
-
|
34
|
42
|
|||
- Crestor
|
|
305
|
3
|
14
|
23
|
|||
- Seloken/Toprol-XL
|
|
179
|
2
|
(27)
|
(20)
|
|||
- Onglyza
|
|
63
|
1
|
(8)
|
(3)
|
|||
- Bydureon
|
|
45
|
-
|
(33)
|
(32)
|
|||
-
Others
|
|
102
|
1
|
4
|
9
|
|||
BioPharmaceuticals: R&I
|
|
1,583
|
15
|
5
|
10
|
|||
- Symbicort
|
|
688
|
6
|
2
|
7
|
|||
- Fasenra
|
|
338
|
3
|
10
|
13
|
|||
- Breztri
|
|
144
|
1
|
67
|
73
|
|||
- Saphnelo
|
|
47
|
-
|
>4x
|
>4x
|
|||
- Tezspire
|
|
11
|
-
|
n/m
|
n/m
|
|||
- Pulmicort
|
|
221
|
2
|
2
|
9
|
|||
- Bevespi
|
|
15
|
-
|
(1)
|
2
|
|||
- Daliresp/Daxas
|
|
13
|
-
|
(75)
|
(75)
|
|||
- Others
|
|
106
|
1
|
(27)
|
(22)
|
|||
BioPharmaceuticals: V&I
|
|
355
|
3
|
(80)
|
(78)
|
|||
-
COVID-19 mAbs
|
|
127
|
1
|
(73)
|
(70)
|
|||
- Vaxzevria
|
|
28
|
-
|
(97)
|
(97)
|
|||
- Synagis
|
|
198
|
2
|
(1)
|
5
|
|||
- FluMist
|
|
2
|
-
|
n/m
|
n/m
|
|||
Rare Disease
|
|
1,866
|
17
|
10
|
14
|
|||
- Soliris
|
|
834
|
8
|
(16)
|
(13)
|
|||
- Ultomiris
|
|
651
|
6
|
55
|
61
|
|||
- Strensiq
|
|
262
|
2
|
26
|
28
|
|||
- Koselugo
|
|
79
|
1
|
>2x
|
>2x
|
|||
- Kanuma
|
|
40
|
-
|
4
|
6
|
|||
Other Medicines
|
|
312
|
3
|
(26)
|
(21)
|
|||
- Nexium
|
|
244
|
2
|
(27)
|
(20)
|
|||
-
Others
|
|
68
|
1
|
(26)
|
(23)
|
|||
Product Sales
|
|
10,566
|
97
|
(4)
|
1
|
|||
Alliance Revenue
|
|
286
|
3
|
88
|
90
|
|||
Collaboration Revenue
|
|
27
|
-
|
(89)
|
(89)
|
|||
Total Revenue
|
|
10,879
|
100
|
(4)
|
-
|
|||
|
|
|
|
|
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
% Change
|
|
|
|
$m
|
% Total
|
Actual
|
CER
|
Enhertu
|
|
220
|
77
|
>2x
|
>2x
|
Tezspire
|
|
43
|
15
|
n/m
|
n/m
|
Vaxzevria: royalties
|
|
-
|
-
|
n/m
|
n/m
|
Other royalty income
|
|
20
|
7
|
23
|
24
|
Other Alliance Revenue
|
|
3
|
1
|
>3x
|
>3x
|
Total
|
|
286
|
100
|
88
|
90
|
|
Q1 2023
|
||||
|
|
|
|
% Change
|
|
|
|
$m
|
% Total
|
Actual
|
CER
|
Farxiga: sales
milestones
|
|
24
|
89
|
n/m
|
n/m
|
Other Collaboration Revenue
|
|
3
|
11
|
(76)
|
(76)
|
Total
|
|
27
|
100
|
(89)
|
(89)
|
|
Q1 2023
|
|
|||||
|
|
% Change
|
|
|
|||
|
|
$m
|
% Total
|
Actual
|
CER
|
||
Oncology
|
|
4,148
|
38
|
14
|
19
|
||
BioPharmaceuticals
|
|
4,545
|
42
|
(19)
|
(15)
|
||
- CVRM
|
|
2,557
|
24
|
15
|
22
|
||
- R&I
|
|
1,633
|
15
|
3
|
8
|
||
- V&I
|
|
355
|
3
|
(80)
|
(79)
|
||
Rare Disease
|
|
1,866
|
17
|
10
|
14
|
||
Other Medicines
|
|
320
|
3
|
(26)
|
(21)
|
||
Total
|
|
10,879
|
100
|
(4)
|
-
|
||
|
|
|
|
|
|
|
|
|
Q1 2023
|
|
|||||||
|
|
|
% Change
|
|
|||||
|
|
$m
|
% Total
|
Actual
|
CER
|
||||
US
|
|
4,299
|
40
|
4
|
4
|
||||
Emerging Markets
|
|
3,162
|
29
|
(6)
|
1
|
||||
- China
|
|
1,602
|
15
|
(1)
|
8
|
||||
- Ex-China
|
|
1,560
|
14
|
(10)
|
(6)
|
||||
Europe
|
|
2,162
|
20
|
(5)
|
-
|
||||
Established RoW
|
|
1,256
|
12
|
(22)
|
(12)
|
||||
Total
|
|
10,879
|
100
|
(4)
|
-
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2023
|
|
|||||||
|
|
|
|
% Change
|
|
|||||
|
|
$m
|
% Total
|
Actual
|
CER
|
|||||
US
|
|
4,299
|
40
|
15
|
15
|
|||||
Emerging Markets
|
|
3,136
|
29
|
14
|
22
|
|||||
- China
|
|
1,602
|
15
|
2
|
11
|
|||||
- Ex-China
|
|
1,534
|
14
|
31
|
38
|
|||||
Europe
|
|
2,148
|
20
|
3
|
9
|
|||||
Established RoW
|
|
1,142
|
11
|
(5)
|
7
|
|||||
Total
|
|
10,725
|
100
|
10
|
15
|
|||||
|
|
|
|
|
|
|
|
|
|
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
1,424
|
|
521
|
444
|
257
|
202
|
Actual change
|
|
9%
|
|
19%
|
9%
|
2%
|
(2%)
|
CER change
|
|
15%
|
|
19%
|
17%
|
8%
|
11%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Increased use of Tagrisso in adjuvant and 1st-line setting and
expansion of reimbursed access
|
US
|
|
∗ Increasing demand in 1st-line and adjuvant
setting, partially offset by unfavourable inventory
movements
|
Emerging Markets
|
|
∗ Rising demand from increased patient access in
China continues to offset NRDL[26] renewal
price reductions
∗ Recovery from Q4 2022 ordering dynamics in
China
|
Europe
|
|
∗ Established standard of care in
1st-line and adjuvant setting across EU5[27],
partially offset by pricing clawbacks in certain
markets
|
Established RoW
|
|
∗ Increased use in 1st-line setting and launch
acceleration in adjuvant, including Japan
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
900
|
|
522
|
81
|
163
|
134
|
Actual change
|
|
50%
|
|
66%
|
39%
|
31%
|
33%
|
CER change
|
|
56%
|
|
66%
|
47%
|
38%
|
52%
|
|
|
|
|
|
|
|
|
Region
|
|
Drivers and commentary
|
|||||
Worldwide
|
|
∗ The Imfinzi revenue line includes sales
of Imjudo, which launched in Q4 2022 following
approvals in the US for patients with unresectable liver cancer
(HIMALAYA) and Stage IV NSCLC (POSEIDON)
∗ Increased use
of Imfinzi in
BTC[28] (TOPAZ-1),
liver cancer (HIMALAYA) and lung cancers (POSEIDON,
CASPIAN)
|
|||||
US
|
|
∗ Continued growth in new patient starts across
Stage III NSCLC and ES-SCLC[29]
∗ Strong launch in BTC following September 2022 FDA
approval, and growing penetration of Imfinzi + Imjudo in liver and lung
cancers
|
|||||
Emerging Markets
|
|
∗ Growth in ex-China driven increased market
penetration in ES-SCLC and NSCLC (PACIFIC), and recovery of
diagnosis and treatment rates following the COVID-19
pandemic
|
|||||
Europe
|
|
∗ Increased market penetration in ES-SCLC, launch
trajectory in BTC, growth in the number of reimbursed
markets
|
|||||
Established RoW
|
|
∗ New reimbursements, strong demand growth in
BTC
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
651
|
|
268
|
137
|
178
|
68
|
Actual change
|
|
(18%)
|
|
(1%)
|
13%
|
(47%)
|
2%
|
CER change
|
|
(14%)
|
|
(1%)
|
19%
|
(44%)
|
16%
|
Product Sales
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
651
|
|
268
|
137
|
178
|
68
|
Actual change
|
|
5%
|
|
(1%)
|
13%
|
11%
|
2%
|
CER change
|
|
10%
|
|
(1%)
|
19%
|
18%
|
16%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Lynparza remains
the leading medicine in the PARP[30] inhibitor
class globally across four tumour types, as measured by total
prescription volume
∗ No regulatory milestones received in Q1
2023
|
US
|
|
∗ Positive demand growth driven by OlympiA (FDA
approval March 2022) offset by flattening HRD testing rates in
ovarian cancer and destocking following an inventory build in Q4
2022 in anticipation of PROpel launch
|
Emerging Markets
|
|
∗ Re-enlistment
into China's NRDL
for ovarian cancer indications
(PSR[31] and
BRCAm[32] 1st-line
maintenance) and new enlistment in prostate cancer
(PROfound)
|
Europe
|
|
∗ Growth driven by increased uptake
in 1st-line HRD-positive ovarian cancer, gBRCAm[33] HER2-negative
early breast cancer and BRCAm mCRPC, partially offset by new
indication pricing impact and clawbacks in some
markets
|
Established RoW
|
|
∗ Growth continues across tumour
types
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
257
|
|
161
|
38
|
55
|
3
|
Actual change
|
|
>2x
|
|
>2x
|
>4x
|
>2x
|
>5x
|
CER change
|
|
>3x
|
|
>2x
|
>4x
|
>2x
|
>6x
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Combined sales of Enhertu, recorded by Daiichi Sankyo Company Limited
(Daiichi Sankyo) and AstraZeneca, amounted to $508m in the quarter
(Q1 2022: $166m)
∗ AstraZeneca's Total Revenue of $257m includes
$220m of Alliance Revenue from its share of gross profit and
royalties in territories where Daiichi Sankyo records product
sales
|
US
|
|
∗ US in-market sales, recorded by Daiichi Sankyo,
amounted to $336m in the quarter (Q1
2022: $119m)
∗ Rapid adoption as new standard of
care across all launched indications including HER2-low
mBC[34] with strong
demand continuing from breast cancer launches
|
Emerging Markets
|
|
∗ Strong uptake driven by new approvals and
launches
|
Europe
|
|
∗ Continued growth in 2nd-line and 3rd-line+
HER2-positive metastatic breast cancer
∗ Increased uptake following launches of 2nd-line+
HER2-positive gastric cancer and 2nd-line+ HER2-low metastatic
breast cancer after EU approvals in December 2022 and January 2023
respectively (DESTINY-Gastric01, DESTINY-Gastric02,
DESTINY-Breast04)
|
Established RoW
|
|
∗ In Japan, AstraZeneca receives a mid-single-digit
percentage royalty on sales made by Daiichi
Sankyo
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
532
|
|
384
|
18
|
108
|
22
|
Actual change
|
|
28%
|
|
13%
|
>2x
|
95%
|
76%
|
CER change
|
|
31%
|
|
13%
|
>2x
|
>2x
|
91%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Increased penetration globally;
leading BTKi[35] in
key markets
|
US
|
|
∗ 1st-line patient share broadly stable, some
competitive impact in relapsed refractory
setting
∗ Q1 2023 performance impacted by destocking
following inventory build-up that followed approval of the maleate
tablet formulation
|
|
|
Q1 2023
|
Change
|
|
|||
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
|
Zoladex
|
|
235
|
(5%)
|
4%
|
∗ Increased use in ex-China Emerging
Markets
|
|
Faslodex
|
|
75
|
(19%)
|
(11%)
|
∗ Generic competition
|
|
Other Oncology
|
|
66
|
(32%)
|
(27%)
|
∗ Includes Iressa, Arimidex, Casodex and other older
medicines
|
|
|
|
|
|
|
|
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
1,324
|
|
296
|
498
|
393
|
138
|
Actual change
|
|
32%
|
|
53%
|
27%
|
24%
|
39%
|
CER change
|
|
39%
|
|
53%
|
35%
|
31%
|
53%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Farxiga volume
is growing faster than the overall SGLT2[37] market
in all major regions
∗ Additional benefit from continued growth in the
overall SGLT2 inhibitor class
∗ Further HF[38] and
CKD[39] launches
and supportive updates to treatment guidelines including from
ESC[40] and
AHA[41]/ACC[42]/HFSA[43].
HF and CKD indications now launched in >100
markets
|
US
|
|
∗ Growth driven by HFrEF[44] and
CKD for patients with and without T2D[45]
∗ Favourable gross-to-net impact in the
quarter
∗ Farxiga continued
to gain in-class brand share, driven by HF and CKD
launches
|
Emerging Markets
|
|
∗ Growth despite generic competition in some
markets. Solid growth in ex-China Emerging Markets, particularly
Latin America
|
Europe
|
|
∗ Benefited from the addition of cardiovascular
outcomes trial data to the label, the HFrEF regulatory approval in
November 2020, and CKD regulatory approval in August 2021.
HFpEF[46] approval
in February 2023
∗ Continued strong volume growth in the quarter
partially offset by clawbacks
|
Established RoW
|
|
∗ In Japan, AstraZeneca sells to collaborator Ono
Pharmaceutical Co., Ltd, which records in-market sales. Continued
volume growth driven by HF and CKD launches. A milestone payment
from Ono was recorded in the quarter
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
334
|
|
179
|
82
|
67
|
6
|
Actual change
|
|
3%
|
|
8%
|
19%
|
(12%)
|
(59%)
|
CER change
|
|
5%
|
|
8%
|
25%
|
(7%)
|
(53%)
|
Region
|
|
Drivers and commentary
|
US
|
|
∗ Favourable comparison due to COVID-19 impact in Q1
2022
|
Emerging Markets
|
|
∗ Growth in all major Emerging Markets regions
following COVID-19 recovery
|
Europe
|
|
∗ European sales negatively impacted by
clawbacks
|
|
Q1 2023
|
Change
|
|
|||
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
|
Crestor
|
|
306
|
14%
|
23%
|
∗ Strong sales growth in Emerging Markets, partly
offset by declines in the US and Established
RoW
|
|
Seloken
|
|
179
|
(27%)
|
(20%)
|
∗ Emerging Markets sales impacted
by China VBP implementation of Betaloc[47] oral
in H2 2021. Betaloc ZOK VBP
was implemented in Q4 2022
|
|
Onglyza
|
|
63
|
(8%)
|
(3%)
|
∗ Continued decline for DPP-IV
class
|
|
Bydureon
|
|
45
|
(33%)
|
(32%)
|
∗ Continued competitive
pressures
|
|
Other CVRM
|
|
102
|
4%
|
9%
|
|
|
|
|
|
|
|
|
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
688
|
|
233
|
229
|
147
|
79
|
Actual change
|
|
2%
|
|
(10%)
|
37%
|
(6%)
|
(14%)
|
CER change
|
|
7%
|
|
(10%)
|
48%
|
(1%)
|
(7%)
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Symbicort remains the global market leader within a
stable ICS[48]/LABA[49] class
|
US
|
|
∗ Market share resilience,
consolidating leadership in a declining ICS/LABA
market
∗ Generic entry expected in the US in
2023
|
Emerging Markets
|
|
∗ Post-COVID-19 recovery in
China and channel inventory rebuild
|
Europe
|
|
∗ Resilient market share in
growing ICS/LABA market, offset by pricing pressure
|
Established RoW
|
|
∗ Inventory destocking in some
markets and generic erosion in Japan
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
338
|
|
201
|
14
|
88
|
35
|
Actual change
|
|
10%
|
|
6%
|
>2x
|
17%
|
(4%)
|
CER change
|
|
13%
|
|
6%
|
>2x
|
23%
|
7%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Continues to be market leader in
severe eosinophilic asthma in major markets, and leads in the
IL-5[50] class
|
US
|
|
∗ Strong underlying demand
growth, partially offset in the quarter by inventory
dynamics
|
Emerging Markets
|
|
∗ Strong volume growth driven by
launch acceleration across key markets
|
Europe
|
|
∗ Expanded leadership in severe
eosinophilic asthma
|
Established RoW
|
|
∗ Maintained leadership of the
dynamic market[51] in
Japan
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
144
|
|
81
|
38
|
15
|
10
|
Actual change
|
|
67%
|
|
53%
|
71%
|
>3x
|
52%
|
CER change
|
|
73%
|
|
53%
|
85%
|
>3x
|
73%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Continues to gain market share
within the growing FDC[52] triple
class across major markets
|
US
|
|
∗ Consistent share growth within the FDC
triple class in new-to-brand[53] and
total market
|
Emerging Markets
|
|
∗ Maintained market share
leadership in China within the FDC triple class
|
Europe
|
|
∗ Sustained growth across
markets as new launches continue to progress
|
Established RoW
|
|
∗ Increasing new-to-brand market share within
COPD plus ACO[54] in
Japan
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
47
|
|
44
|
-
|
1
|
2
|
Actual change
|
|
>4x
|
|
>4x
|
n/m
|
>3x
|
>4x
|
CER change
|
|
>4x
|
|
>4x
|
n/m
|
>4x
|
>5x
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Demand acceleration in the US,
where Saphnelo has
new-to-brand leadership in the i.v.[55]
segment for SLE[56],
and the ongoing launches in Europe and Japan
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
54
|
|
43
|
-
|
7
|
4
|
Actual change
|
|
>10x
|
|
>10x
|
n/m
|
n/m
|
n/m
|
CER change
|
|
>10x
|
|
>10x
|
n/m
|
n/m
|
n/m
|
|
Q1 2023
|
% Change
|
|
||||
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
||
Pulmicort
|
|
221
|
2%
|
9%
|
∗ Revenues increased in Emerging
Markets with continued recovery of nebulisation demand post
COVID-19 and market share in China stabilising
∗ Revenue from the US declined
54%
|
||
Bevespi
|
|
15
|
(1%)
|
2%
|
|
||
Daliresp
|
|
13
|
(75%)
|
(75%)
|
∗ Impacted by uptake of multiple
generics following loss of exclusivity in the US
|
||
Other R&I
|
|
113
|
(48%)
|
(45%)
|
∗ Collaboration Revenue of $nil (Q1 2022:
$70m)
∗ Product Sales of $106m decreased 27% (22% at CER)
due to generic competition
|
||
|
|
|
|
|
|
|
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
127
|
|
-
|
8
|
4
|
115
|
Actual change
|
|
(73%)
|
|
n/m
|
(91%)
|
(94%)
|
>10x
|
CER change
|
|
(70%)
|
|
n/m
|
(91%)
|
(94%)
|
>10x
|
Region
|
|
Drivers and commentary
|
US
|
|
∗ No revenue in the quarter following the completion
of US government contract deliveries in Q4 2022, and the revision
of Evusheld's emergency use authorisation in January
2023
|
Established RoW
|
|
∗ Deliveries in Japan
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
28
|
|
-
|
18
|
10
|
-
|
Actual change
|
|
(98%)
|
|
n/m
|
(97%)
|
(93%)
|
n/m
|
CER change
|
|
(97%)
|
|
n/m
|
(97%)
|
(92%)
|
n/m
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Revenue in the quarter decreased by 98% (97% at
CER) due to the conclusion of Vaxzevria contracts
|
|
Q1 2023
|
% Change
|
|
||||
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
||
Synagis
|
|
198
|
(1%)
|
5%
|
|
||
FluMist
|
|
2
|
n/m
|
n/m
|
∗ Normal
seasonality
|
||
|
|
|
|
|
|
|
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
834
|
|
448
|
115
|
183
|
88
|
Actual change
|
|
(16%)
|
|
(24%)
|
63%
|
(17%)
|
(18%)
|
CER change
|
|
(13%)
|
|
(24%)
|
77%
|
(12%)
|
(10%)
|
Region
|
|
Drivers and commentary
|
US
|
|
∗ Performance impacted by
successful conversion of Soliris patients
to Ultomiris in
PNH, aHUS[58] and
gMG[59],
partially offset by Soliris growth
in NMOSD
|
Emerging Markets
|
|
∗ Growth from expansion into new markets and
favourable timing of tender orders in some
markets
|
Europe,Established RoW
|
|
∗ Decline driven by successful conversion
of Soliris patients to Ultomiris, slightly offset by growth in
NMOSD
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
651
|
|
381
|
13
|
159
|
98
|
Actual change
|
|
55%
|
|
73%
|
(46%)
|
52%
|
39%
|
CER change
|
|
61%
|
|
73%
|
(45%)
|
61%
|
61%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Performance driven by gMG launch in the US and
expansion into new markets
∗ Quarter-on-quarter variability in revenue growth
can be expected due to Ultomiris every eight-week dosing schedule and lower
average annual treatment cost per patient compared
to Soliris
|
US
|
|
∗ Performance driven by successful conversion
from Soliris across PNH, aHUS and gMG
|
Emerging Markets
|
|
∗ Impacted by inventory movements at third-party
distributors due to AstraZeneca bringing distribution
in-house
|
Europe
|
|
∗ Growth driven by strong demand generation
following new launch markets
|
Established RoW
|
|
∗ Rapid conversion from Soliris in Japan
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
Q1 2023 $m
|
|
262
|
|
205
|
15
|
21
|
21
|
Actual change
|
|
26%
|
|
28%
|
70%
|
10%
|
7%
|
CER change
|
|
28%
|
|
28%
|
58%
|
17%
|
22%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
∗ Performance driven by strong patient demand and
geographic expansion
|
|
Q1 2023
|
% Change
|
|
||||
Total Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
||
Koselugo
|
|
79
|
>2x
|
>2x
|
∗ Growth driven by expansion in new
markets
|
||
Kanuma
|
|
40
|
4%
|
6%
|
∗ Continued demand growth in ex-US
markets
|
||
|
|
|
|
|
|
|
|
|
Q1 2023
|
% Change
|
|
||||
Total Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
||
Nexium
|
|
248
|
(26%)
|
(20%)
|
∗ Generic launches in Japan in the latter part of
2022
|
||
Others
|
|
72
|
(26%)
|
(22%)
|
∗ Continued impact of generic
competition
|
||
|
|
|
|
|
|
|
|
|
|
Q1 2023
|
Q1 2022
|
% Change
|
|
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
|
10,879
|
11,390
|
(4)
|
-
|
|
- Product Sales
|
|
10,566
|
10,980
|
(4)
|
1
|
|
- Alliance Revenue
|
|
286
|
152
|
88
|
90
|
|
- Collaboration Revenue
|
|
27
|
258
|
(89)
|
(89)
|
|
Cost of sales
|
|
(1,905)
|
(3,511)
|
(46)
|
(43)
|
|
Gross profit
|
|
8,974
|
7,879
|
14
|
19
|
|
Gross Margin
|
|
82.0%
|
68.0%
|
+14pp
|
+14pp
|
|
Distribution expense
|
|
(134)
|
(125)
|
7
|
12
|
|
% Total Revenue
|
|
1.2%
|
1.1%
|
-
|
-
|
|
R&D expense
|
|
(2,611)
|
(2,133)
|
22
|
28
|
|
% Total Revenue
|
|
24.0%
|
18.7%
|
-5pp
|
-5pp
|
|
SG&A expense
|
|
(4,059)
|
(4,840)
|
(16)
|
(13)
|
|
% Total Revenue
|
|
37.3%
|
42.5%
|
+5pp
|
+5pp
|
|
OOI[60] &
expense
|
|
379
|
97
|
>3x
|
>3x
|
|
% Total Revenue
|
|
3.5%
|
0.9%
|
+3pp
|
+2pp
|
|
Operating profit
|
|
2,549
|
878
|
>2x
|
>2x
|
|
Operating Margin
|
|
23.4%
|
7.7%
|
+16pp
|
+16pp
|
|
Net finance expense
|
|
(287)
|
(319)
|
(10)
|
(8)
|
|
Joint ventures and associates
|
|
-
|
(6)
|
(96)
|
(96)
|
|
Profit before tax
|
|
2,262
|
553
|
>4x
|
>4x
|
|
Taxation
|
|
(458)
|
(165)
|
>2x
|
>2x
|
|
Tax rate
|
|
20%
|
30%
|
|
|
|
Profit after tax
|
|
1,804
|
388
|
>4x
|
>4x
|
|
Earnings per share
|
|
$1.16
|
$0.25
|
>4x
|
>4x
|
|
|
|
|
|
|
|
|
|
|
Q1 2023
|
Q1 2022
|
% Change
|
|
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit before tax
|
|
2,262
|
553
|
>4x
|
>4x
|
|
Net finance expense
|
|
287
|
319
|
(10)
|
(8)
|
|
Joint ventures and associates
|
|
-
|
6
|
(96)
|
(96)
|
|
Depreciation, amortisation and impairment
|
|
1,502
|
1,309
|
15
|
18
|
|
EBITDA
|
|
4,051
|
2,187
|
85
|
92
|
|
|
|
|
|
|
|
|
Q1 2023
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisitionof Alexion
|
Other
|
Core
|
Core
% Change
|
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross profit
|
|
8,974
|
95
|
8
|
37
|
2
|
9,116
|
-
|
4
|
|
Gross Margin
|
|
82.0%
|
|
|
|
|
83.3%
|
+4pp
|
+4pp
|
|
Distribution expense
|
|
(134)
|
-
|
-
|
-
|
-
|
(134)
|
8
|
13
|
|
R&D expense
|
|
(2,611)
|
30
|
280
|
2
|
(1)
|
(2,300)
|
5
|
10
|
|
SG&A expense
|
|
(4,059)
|
41
|
954
|
2
|
8
|
(3,054)
|
4
|
8
|
|
Total operating expense
|
|
(6,804)
|
71
|
1,234
|
4
|
7
|
(5,488)
|
4
|
9
|
|
Other operating income & expense
|
|
379
|
(61)
|
-
|
-
|
-
|
318
|
>3x
|
>3x
|
|
Operating profit
|
|
2,549
|
105
|
1,242
|
41
|
9
|
3,946
|
-
|
4
|
|
Operating Margin
|
|
23.4%
|
|
|
|
|
36.3%
|
+2pp
|
+1pp
|
|
Net finance expense
|
|
(287)
|
-
|
-
|
-
|
47
|
(240)
|
(4)
|
(3)
|
|
Taxation
|
|
(458)
|
(24)
|
(231)
|
(9)
|
(9)
|
(731)
|
(5)
|
(1)
|
|
EPS
|
|
$1.16
|
$0.05
|
$0.66
|
$0.02
|
$0.03
|
$1.92
|
1
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2023
|
Q1 2022
|
Change
|
|
|
$m
|
$m
|
$m
|
Reported Operating profit
|
|
2,549
|
878
|
1,671
|
Depreciation, amortisation and impairment
|
|
1,502
|
1,309
|
193
|
Decrease in working capital and short-term provisions
|
|
242
|
1,804
|
(1,562)
|
Gains on disposal of intangible assets
|
|
(249)
|
(10)
|
(239)
|
Non-cash and other movements
|
|
(429)
|
(327)
|
(102)
|
Interest paid
|
|
(257)
|
(194)
|
(63)
|
Taxation paid
|
|
(225)
|
(228)
|
3
|
Net cash inflow from operating activities
|
|
3,133
|
3,232
|
(99)
|
Net cash inflow before financing activities
|
|
1,887
|
3,064
|
(1,177)
|
Net cash outflow from financing activities
|
|
(2,031)
|
(3,740)
|
1,709
|
|
|
At 31
Mar 2023
|
At 31
Dec 2022
|
At 31
Mar 2022
|
|
|
$m
|
$m
|
$m
|
Cash and cash equivalents
|
|
6,232
|
6,166
|
5,762
|
Other investments
|
|
230
|
239
|
61
|
Cash and investments
|
|
6,462
|
6,405
|
5,823
|
Overdrafts and short-term borrowings
|
|
(667)
|
(350)
|
(805)
|
Lease liabilities
|
|
(962)
|
(953)
|
(949)
|
Current instalments of loans
|
|
(2,958)
|
(4,964)
|
(1,264)
|
Non-current instalments of loans
|
|
(26,916)
|
(22,965)
|
(28,081)
|
Interest-bearing loans and borrowings (Gross debt)
|
|
(31,503)
|
(29,232)
|
(31,099)
|
Net derivatives
|
|
(21)
|
(96)
|
59
|
Net debt
|
|
(25,062)
|
(22,923)
|
(25,217)
|
|
|
Q1 2023
|
Q1 2022
|
|
|
$m
|
$m
|
Total Revenue
|
|
-
|
-
|
Gross profit
|
|
-
|
-
|
Operating loss
|
|
-
|
(1)
|
Loss for the period
|
|
(237)
|
(155)
|
Transactions with subsidiaries that are not issuers or
guarantors
|
|
7,502
|
164
|
|
|
At 31 Mar 2023
|
At 31 Mar 2022
|
|
|
$m
|
$m
|
Current assets
|
|
10
|
19
|
Non-current assets
|
|
-
|
-
|
Current liabilities
|
|
(2,952)
|
(1,682)
|
Non-current liabilities
|
|
(26,747)
|
(25,605)
|
Amounts due from subsidiaries that are not issuers or
guarantors
|
|
14,067
|
8,652
|
Amounts due to subsidiaries that are not issuers or
guarantors
|
|
(296)
|
(297)
|
|
|
|
Average
rates vs USD
|
|
Annual impact ($m) of 5% strengthening (FY2023 average rate vs FY 2022
average) [62]
|
|||||||||||||
Currency
|
Primary Relevance
|
|
FY 2022[63]
|
YTD 2023[64]
|
Change
(%)
|
Mar 2023[65]
|
Change[66]
(%)
|
|
Total Revenue
|
Core Operating Profit
|
||||||||
EUR
|
Total Revenue
|
|
0.95
|
0.93
|
2
|
0.93
|
2
|
|
323
|
159
|
||||||||
CNY
|
Total Revenue
|
|
6.74
|
6.85
|
(1)
|
6.90
|
(2)
|
|
309
|
174
|
||||||||
JPY
|
Total Revenue
|
|
131.59
|
132.35
|
(1)
|
133.77
|
(2)
|
|
181
|
122
|
||||||||
Other[67]
|
|
|
|
|
|
|
|
|
385
|
202
|
||||||||
GBP
|
Operating expense
|
|
0.81
|
0.82
|
(2)
|
0.82
|
(2)
|
|
46
|
(92)
|
||||||||
SEK
|
Operating expense
|
|
10.12
|
10.43
|
(3)
|
10.47
|
(3)
|
|
7
|
(55)
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Event
|
|
|
Commentary
|
Phase III trial read out
|
ADAURA
|
|
Met key secondary endpoint demonstrating statistically
significant and clinically meaningful improvement in
OS[68] compared
to placebo in the adjuvant treatment of patients with early-stage
EGFRm[69] NSCLC
after complete tumour resection with curative intent. (March
2023)
|
Event
|
|
|
Commentary
|
Approval
|
EU
|
|
Imfinzi in combination
with Imjudo for the 1st-line treatment of adult patients
with advanced or unresectable HCC. (HIMALAYA, February
2023)
|
|
|
|
Imfinzi in combination
with Imjudo for the treatment of adult patients with
metastatic NSCLC. (POSEIDON, February 2023)
|
Presentation: AACR
|
AEGEAN
|
|
Results from interim EFS analysis of the AEGEAN Phase III trial,
presented at AACR, demonstrated statistically significant and
clinically meaningful 32% reduction in risk of disease recurrence,
progression events or death for Imfinzi in combination with neoadjuvant chemotherapy
before surgery and as adjuvant monotherapy after surgery versus
neoadjuvant chemotherapy alone followed by surgery for patients
with resectable early-stage NSCLC. (April 2023)
|
Event
|
|
|
Commentary
|
Presentation: ASCO GU
|
PROpel final OS
|
|
Results from the final prespecified OS analysis of the PROpel Phase
III trial, presented at ASCO GU,
demonstrated Lynparza in combination with abiraterone resulted in
median OS improvement of 7.4-months vs standard of care in mCRPC
(not statistically significant). (February
2023)
|
FDA ODAC
|
US
|
|
The FDA will convene a meeting of the ODAC on 28 April 2023 to
discuss the sNDA[70] for Lynparza in
combination with abiraterone for the treatment of mCRPC. (PROpel,
March 2023)
|
Phase III trial read-out
|
DUO-O (Lynparza and Imfinzi)
|
|
Met primary endpoint demonstrating a statistically significant and
clinically meaningful improvement in PFS versus chemotherapy plus
bevacizumab in newly diagnosed patients with advanced high-grade
epithelial ovarian cancer without tumour BRCA mutations. (April
2023)
|
Event
|
|
|
Commentary
|
Approval
|
EU
|
|
Maleate tablet formulation. (ELEVATE-PLUS, February
2023)
|
Conditional approval
|
China
|
|
Patients with mantle cell lymphoma who have received at least one
prior therapy. (ACE-LY-004 and Phase I/II trial in Chinese
patients, March 2023)
|
Event
|
|
|
Commentary
|
Approval
|
China
|
|
Patients with unresectable or metastatic HER2-positive breast
cancer who have received one or more prior anti-HER2-based
regimens, based on DESTINY-Breast03 trial. (February
2023)
|
Phase II read out
|
DESTINY-PanTumor02
|
|
Met the prespecified target for objective response rate and
demonstrated durable response across multiple HER2-expressing
advanced solid tumours in heavily pre-treated patients.
(DESTINY-PanTumor02, March 2023)
|
Event
|
|
|
Commentary
|
Presentation: AAN
|
NEURO-TTRansform
|
|
Detailed results from the NEURO-TTRansform Phase III trial in
patients with hereditary transthyretin-mediated amyloid
polyneuropathy (ATTRv-PN) presented at the American Academy of
Neurology (AAN) 2023 Annual Meeting showed that eplontersen met all
co-primary and secondary endpoints at 66 weeks versus an external
placebo group. (April 2023).
|
Event
|
|
|
Commentary
|
Termination
|
PROXYMO ADVANCE
|
|
Strategic decision to discontinue the development of once-daily
cotadutide and focus on AZD9550, a once-weekly injectable GLP-1
glucagon co-agonist, and the broader NASH pipeline. (March
2023)
|
Event
|
|
|
Commentary
|
Phase III trial read-out
|
MIRACLE
|
|
Met the primary endpoint, demonstrating a statistically significant
reduction in annual asthma exacerbation rate (AAER) over 48 weeks
compared to placebo in patients in China with a history of
uncontrolled asthma.
|
Phase III trial read-out
|
TATE
|
|
Met the primary endpoints, demonstrating that the safety and
tolerability profile in severe eosinophilic asthma patients aged 6
to 11 years was consistent with previous trials in patients ages 12
years and older.
|
Event
|
|
|
Commentary
|
Presentation: ECCMID 2023
|
US
|
|
AstraZeneca presented the first in vitro neutralisation data on
AZD3152, including activity against past and currently circulating
COVID-19 variants. The data showed that AZD3152 neutralises all
known variants of concern to date. (April 2023)
|
Event
|
|
|
Commentary
|
Regulatory approval
|
Japan
|
|
As previously announced in 2015, Daiichi Sankyo has responsibility
for the development and commercialisation
of FluMist Quadrivalent in
Japan, and holds the marketing authorisation following approval in
Japan in March 2023. AstraZeneca will
supply FluMist Quadrivalent to
Daiichi Sankyo, and will receive development milestones and
sales-related payments post launch. (March
2023)
|
Event
|
|
|
Commentary
|
Publication: Nature
|
MELODY
|
|
Serum samples were collected from 2,143 infants to characterise the
duration of RSV nAb[71] levels
following nirsevimab administration. Nirsevimab recipients had RSV
nAb levels >140-fold higher than baseline at day 31, and
remained >50-fold
higher at day 151 and >7-fold higher at day 361. (April
2023)
|
Presentation: ECCMID 2023
|
MUSIC
|
|
At ECCMID 2023, AstraZeneca presented results from the MUSIC trial
for nirsevimab in immunocompromised children ≤ 24 months of
age. A single dose of nirsevimab was well tolerated and no safety
concerns arose over 151 days. (April 2023)
|
Contract update
|
|
|
In April 2023, AstraZeneca, Sanofi and Sobi simplified their
contractual arrangements relating to the development and
commercialisation of nirsevimab in the US. The updated arrangements
replaced the cash flows from AstraZeneca to Sobi with a royalty
relationship between Sanofi and Sobi. Sanofi continues to lead
commercialisation globally, and AstraZeneca will
co-promote Beyfortus in the UK, Germany, Italy, Spain, Japan and
China. (April 2023)
|
Event
|
|
|
Commentary
|
Positive opinion
|
EU
|
|
Recommended for approval in the EU by CHMP for the treatment of
adults with NMOSD
|
Event
|
|
|
Commentary
|
Termination
|
Wilson Disease programme
|
|
In April, the ALXN1840 programme in Wilson Disease was terminated.
The decision was based on feedback from regulators, on review of
data from the Wilson Disease programme, including the Phase III
FoCus and two Phase II mechanistic trials
|
For the quarter ended 31 March
|
|
2023
|
2022
|
|
|
$m
|
$m
|
Total
Revenue[72]
|
|
10,879
|
11,390
|
Product Sales
|
|
10,566
|
10,980
|
Alliance Revenue
|
|
286
|
152
|
Collaboration Revenue
|
|
27
|
258
|
Cost of sales
|
|
(1,905)
|
(3,511)
|
Gross profit
|
|
8,974
|
7,879
|
Distribution expense
|
|
(134)
|
(125)
|
Research and development expense
|
|
(2,611)
|
(2,133)
|
Selling, general and administrative expense
|
|
(4,059)
|
(4,840)
|
Other operating income and expense
|
|
379
|
97
|
Operating profit
|
|
2,549
|
878
|
Finance income
|
|
78
|
17
|
Finance expense
|
|
(365)
|
(336)
|
Share of after tax losses in associates and joint
ventures
|
|
-
|
(6)
|
Profit before tax
|
|
2,262
|
553
|
Taxation
|
|
(458)
|
(165)
|
Profit for the period
|
|
1,804
|
388
|
Other comprehensive income
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
Remeasurement of the defined benefit pension liability
|
|
(10)
|
335
|
Net gains on equity investments measured at fair value through
other comprehensive income
|
|
46
|
18
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
|
2
|
-
|
Tax on items that will not be reclassified to profit or
loss
|
|
24
|
(94)
|
|
|
62
|
259
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
Foreign exchange arising on consolidation
|
|
314
|
(219)
|
Foreign exchange arising on designated liabilities in net
investment hedges
|
|
(7)
|
(32)
|
Fair value movements on cash flow hedges
|
|
56
|
5
|
Fair value movements on cash flow hedges transferred to profit and
loss
|
|
(75)
|
11
|
Fair value movements on derivatives designated in net investment
hedges
|
|
16
|
(8)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
|
12
|
1
|
|
|
316
|
(242)
|
Other comprehensive income, net of tax
|
|
378
|
17
|
Total comprehensive income for the period
|
|
2,182
|
405
|
Profit attributable to:
|
|
|
|
Owners of the Parent
|
|
1,803
|
386
|
Non-controlling interests
|
|
1
|
2
|
|
|
1,804
|
388
|
Total comprehensive income attributable to:
|
|
|
|
Owners of the Parent
|
|
2,181
|
405
|
Non-controlling interests
|
|
1
|
-
|
|
|
2,182
|
405
|
Basic earnings per $0.25 Ordinary Share
|
|
$1.16
|
$0.25
|
Diluted earnings per $0.25 Ordinary Share
|
|
$1.16
|
$0.25
|
Weighted average number of Ordinary Shares in issue
(millions)
|
|
1,549
|
1,548
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
|
1,560
|
1,561
|
|
|
At 31 Mar
2023
|
At 31 Dec
2022
|
At 31 Mar
2022
|
|
|
$m
|
$m
|
$m
|
Assets
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property, plant and equipment
|
|
8,644
|
8,507
|
9,061
|
Right-of-use assets
|
|
955
|
942
|
954
|
Goodwill
|
|
20,001
|
19,820
|
19,963
|
Intangible assets
|
|
39,291
|
39,307
|
41,265
|
Investments in associates and joint ventures
|
|
77
|
76
|
63
|
Other investments
|
|
1,157
|
1,066
|
1,174
|
Derivative financial instruments
|
|
116
|
74
|
87
|
Other receivables
|
|
682
|
835
|
864
|
Deferred tax assets
|
|
3,498
|
3,263
|
4,195
|
|
|
74,421
|
73,890
|
77,626
|
Current assets
|
|
|
|
|
Inventories
|
|
4,967
|
4,699
|
7,624
|
Trade and other receivables
|
|
10,289
|
10,521
|
8,683
|
Other investments
|
|
230
|
239
|
61
|
Derivative financial instruments
|
|
40
|
87
|
54
|
Intangible assets
|
|
-
|
-
|
96
|
Income tax receivable
|
|
508
|
731
|
367
|
Cash and cash equivalents
|
|
6,232
|
6,166
|
5,762
|
Assets held for sale
|
|
-
|
150
|
-
|
|
|
22,266
|
22,593
|
22,647
|
Total assets
|
|
96,687
|
96,483
|
100,273
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(3,625)
|
(5,314)
|
(2,069)
|
Lease liabilities
|
|
(232)
|
(228)
|
(225)
|
Trade and other payables
|
|
(19,210)
|
(19,040)
|
(17,864)
|
Derivative financial instruments
|
|
(44)
|
(93)
|
(35)
|
Provisions
|
|
(546)
|
(722)
|
(1,423)
|
Income tax payable
|
|
(1,203)
|
(896)
|
(1,124)
|
|
|
(24,860)
|
(26,293)
|
(22,740)
|
Non-current liabilities
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(26,916)
|
(22,965)
|
(28,081)
|
Lease liabilities
|
|
(730)
|
(725)
|
(724)
|
Derivative financial instruments
|
|
(133)
|
(164)
|
(47)
|
Deferred tax liabilities
|
|
(2,795)
|
(2,944)
|
(5,626)
|
Retirement benefit obligations
|
|
(1,128)
|
(1,168)
|
(1,991)
|
Provisions
|
|
(914)
|
(896)
|
(949)
|
Other payables
|
|
(3,400)
|
(4,270)
|
(3,756)
|
|
|
(36,016)
|
(33,132)
|
(41,174)
|
Total liabilities
|
|
(60,876)
|
(59,425)
|
(63,914)
|
Net assets
|
|
35,811
|
37,058
|
36,359
|
Equity
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
|
Share capital
|
|
387
|
387
|
387
|
Share premium account
|
|
35,159
|
35,155
|
35,131
|
Other reserves
|
|
2,068
|
2,069
|
2,050
|
Retained earnings
|
|
(1,825)
|
(574)
|
(1,228)
|
|
|
35,789
|
37,037
|
36,340
|
Non-controlling interests
|
|
22
|
21
|
19
|
Total equity
|
|
35,811
|
37,058
|
36,359
|
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2022
|
|
387
|
35,126
|
2,045
|
1,710
|
39,268
|
19
|
39,287
|
Profit for the period
|
|
-
|
-
|
-
|
386
|
386
|
2
|
388
|
Other comprehensive income
|
|
-
|
-
|
-
|
19
|
19
|
(2)
|
17
|
Transfer to other reserves
|
|
-
|
-
|
5
|
(5)
|
-
|
-
|
-
|
Transactions with owners
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(3,046)
|
(3,046)
|
-
|
(3,046)
|
Issue of Ordinary Shares
|
|
-
|
5
|
-
|
-
|
5
|
-
|
5
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
182
|
182
|
-
|
182
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(474)
|
(474)
|
-
|
(474)
|
Net movement
|
|
-
|
5
|
5
|
(2,938)
|
(2,928)
|
-
|
(2,928)
|
At 31 Mar 2022
|
|
387
|
35,131
|
2,050
|
(1,228)
|
36,340
|
19
|
36,359
|
|
|
|
|
|
|
|
|
|
At 1 Jan 2023
|
|
387
|
35,155
|
2,069
|
(574)
|
37,037
|
21
|
37,058
|
Profit for the period
|
|
-
|
-
|
-
|
1,803
|
1,803
|
1
|
1,804
|
Other comprehensive income
|
|
-
|
-
|
-
|
378
|
378
|
-
|
378
|
Transfer to other reserves
|
|
-
|
-
|
(1)
|
1
|
-
|
-
|
-
|
Transactions with owners
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(3,047)
|
(3,047)
|
-
|
(3,047)
|
Issue of Ordinary Shares
|
|
-
|
4
|
-
|
-
|
4
|
-
|
4
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
132
|
132
|
-
|
132
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(518)
|
(518)
|
-
|
(518)
|
Net movement
|
|
-
|
4
|
(1)
|
(1,251)
|
(1,248)
|
1
|
(1,247)
|
At 31 Mar 2023
|
|
387
|
35,159
|
2,068
|
(1,825)
|
35,789
|
22
|
35,811
|
For the quarter ended 31 March
|
|
2023
|
2022
|
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
|
Profit before tax
|
|
2,262
|
553
|
Finance income and expense
|
|
287
|
319
|
Share of after tax losses of associates and joint
ventures
|
|
-
|
6
|
Depreciation, amortisation and impairment
|
|
1,502
|
1,309
|
Decrease in working capital and short-term provisions
|
|
242
|
1,804
|
Gains on disposal of intangible assets
|
|
(249)
|
(10)
|
Non-cash
and other movements
|
|
(429)
|
(327)
|
Cash generated from operations
|
|
3,615
|
3,654
|
Interest paid
|
|
(257)
|
(194)
|
Tax paid
|
|
(225)
|
(228)
|
Net cash inflow from operating activities
|
|
3,133
|
3,232
|
Cash flows from investing activities
|
|
|
|
Acquisition of subsidiaries, net of cash acquired
|
|
(189)
|
-
|
Payments upon vesting of employee share awards attributable to
business combinations
|
|
(23)
|
(55)
|
Payment of contingent consideration from business
combinations
|
|
(214)
|
(182)
|
Purchase of property, plant and equipment
|
|
(247)
|
(219)
|
Disposal of property, plant and equipment
|
|
125
|
-
|
Purchase of intangible assets
|
|
(1,223)
|
(144)
|
Disposal of intangible assets
|
|
264
|
385
|
Movement in profit-participation liability
|
|
175
|
-
|
Purchase of non-current asset investments
|
|
-
|
(4)
|
Disposal of non-current asset investments
|
|
10
|
32
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
|
9
|
21
|
Payments to associates and joint ventures
|
|
-
|
(5)
|
Interest received
|
|
67
|
3
|
Net cash outflow from investing activities
|
|
(1,246)
|
(168)
|
Net cash inflow before financing activities
|
|
1,887
|
3,064
|
Cash flows from financing activities
|
|
|
|
Proceeds from issue of share capital
|
|
4
|
5
|
Issue of loans and borrowings
|
|
3,826
|
-
|
Repayment of loans and borrowings
|
|
(2,004)
|
(4)
|
Dividends paid
|
|
(3,047)
|
(2,971)
|
Hedge contracts relating to dividend payments
|
|
27
|
(77)
|
Repayment of obligations under leases
|
|
(67)
|
(74)
|
Movement in short-term borrowings
|
|
97
|
301
|
Payment of Acerta Pharma share purchase liability
|
|
(867)
|
(920)
|
Net cash outflow from financing activities
|
|
(2,031)
|
(3,740)
|
Net decrease in Cash and cash equivalents in the
period
|
|
(144)
|
(676)
|
Cash and cash equivalents at the beginning of the
period
|
|
5,983
|
6,038
|
Exchange rate effects
|
|
(11)
|
(9)
|
Cash and cash equivalents at the end of the period
|
|
5,828
|
5,353
|
Cash and cash equivalents consist of:
|
|
|
|
Cash and cash equivalents
|
|
6,232
|
5,762
|
Overdrafts
|
|
(404)
|
(409)
|
|
|
5,828
|
5,353
|
|
|
At 1 Jan 2023
|
Cash flow
|
Acquisitions
|
Non-cash& other
|
Exchange movements
|
At 31 Mar 2023
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Non-current instalments of loans
|
|
(22,965)
|
(3,826)
|
-
|
(7)
|
(118)
|
(26,916)
|
Non-current instalments of leases
|
|
(725)
|
-
|
(6)
|
6
|
(5)
|
(730)
|
Total long-term debt
|
|
(23,690)
|
(3,826)
|
(6)
|
(1)
|
(123)
|
(27,646)
|
Current instalments of loans
|
|
(4,964)
|
2,004
|
-
|
2
|
-
|
(2,958)
|
Current instalments of leases
|
|
(228)
|
72
|
(2)
|
(73)
|
(1)
|
(232)
|
Commercial paper
|
|
-
|
(74)
|
-
|
-
|
-
|
(74)
|
Bank collateral received
|
|
(89)
|
(10)
|
-
|
-
|
-
|
(99)
|
Other short-term borrowings excluding overdrafts
|
|
(78)
|
(13)
|
-
|
-
|
1
|
(90)
|
Overdrafts
|
|
(183)
|
(218)
|
-
|
-
|
(3)
|
(404)
|
Total current debt
|
|
(5,542)
|
1,761
|
(2)
|
(71)
|
(3)
|
(3,857)
|
Gross borrowings
|
|
(29,232)
|
(2,065)
|
(8)
|
(72)
|
(126)
|
(31,503)
|
Net derivative financial instruments
|
|
(96)
|
(17)
|
-
|
92
|
-
|
(21)
|
Net borrowings
|
|
(29,328)
|
(2,082)
|
(8)
|
20
|
(126)
|
(31,524)
|
Cash and cash equivalents
|
|
6,166
|
74
|
-
|
-
|
(8)
|
6,232
|
Other investments - current
|
|
239
|
(9)
|
-
|
-
|
-
|
230
|
Cash and investments
|
|
6,405
|
65
|
-
|
-
|
(8)
|
6,462
|
Net debt
|
|
(22,923)
|
(2,017)
|
(8)
|
20
|
(134)
|
(25,062)
|
|
|
2023
|
2022
|
|||||
|
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|||
|
|
$m
|
$m
|
$m
|
$m
|
|||
At 1 January
|
|
2,124
|
98
|
2,222
|
2,865
|
|||
Additions through business combinations
|
|
-
|
60
|
60
|
-
|
|||
Settlements
|
|
(212)
|
(2)
|
(214)
|
(182)
|
|||
Disposals
|
|
-
|
-
|
-
|
(121)
|
|||
Discount unwind
|
|
31
|
2
|
33
|
42
|
|||
At 31 March
|
|
1,943
|
158
|
2,101
|
2,604
|
|||
|
|
|
|
|
|
|
|
|
|
World
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
|||||||||
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
|
Oncology
|
3,920
|
16
|
21
|
1,704
|
24
|
966
|
8
|
16
|
760
|
17
|
24
|
490
|
4
|
19
|
|
Tagrisso
|
1,424
|
9
|
15
|
521
|
19
|
444
|
9
|
17
|
257
|
2
|
8
|
202
|
(2)
|
11
|
|
Imfinzi
|
900
|
50
|
56
|
522
|
66
|
81
|
39
|
47
|
163
|
31
|
38
|
134
|
33
|
52
|
|
Lynparza
|
651
|
5
|
10
|
268
|
(1)
|
137
|
13
|
19
|
178
|
11
|
18
|
68
|
2
|
16
|
|
Calquence
|
532
|
28
|
31
|
384
|
13
|
18
|
n/m
|
n/m
|
108
|
95
|
n/m
|
22
|
76
|
91
|
|
Enhertu
|
37
|
n/m
|
n/m
|
-
|
-
|
24
|
n/m
|
n/m
|
10
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
|
Orpathys
|
8
|
(33)
|
(27)
|
-
|
-
|
8
|
(33)
|
(27)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Zoladex
|
227
|
(6)
|
3
|
3
|
(25)
|
167
|
-
|
10
|
33
|
(5)
|
1
|
24
|
(32)
|
(22)
|
|
Faslodex
|
75
|
(19)
|
(11)
|
4
|
(33)
|
37
|
(14)
|
(7)
|
10
|
(39)
|
(35)
|
24
|
(13)
|
1
|
|
Others
|
66
|
(32)
|
(27)
|
2
|
(28)
|
50
|
(31)
|
(27)
|
1
|
(55)
|
(52)
|
13
|
(32)
|
(22)
|
|
BioPharmaceuticals: CVRM
|
2,530
|
15
|
21
|
622
|
19
|
1,165
|
14
|
22
|
557
|
16
|
22
|
186
|
4
|
19
|
|
Farxiga
|
1,299
|
30
|
37
|
296
|
53
|
498
|
27
|
35
|
393
|
24
|
31
|
112
|
15
|
29
|
|
Brilinta
|
334
|
3
|
5
|
179
|
8
|
82
|
19
|
25
|
67
|
(12)
|
(7)
|
6
|
(59)
|
(53)
|
|
Lokelma
|
98
|
56
|
64
|
56
|
45
|
11
|
n/m
|
n/m
|
11
|
98
|
n/m
|
20
|
29
|
50
|
|
roxadustat
|
61
|
49
|
63
|
-
|
-
|
61
|
49
|
63
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Andexxa
|
44
|
34
|
42
|
20
|
(13)
|
-
|
-
|
-
|
15
|
58
|
66
|
9
|
n/m
|
n/m
|
|
Crestor
|
305
|
14
|
23
|
14
|
(22)
|
241
|
22
|
32
|
16
|
48
|
56
|
34
|
(18)
|
(7)
|
|
Seloken/Toprol-XL
|
179
|
(27)
|
(20)
|
-
|
-
|
173
|
(27)
|
(21)
|
4
|
3
|
(3)
|
2
|
(23)
|
(19)
|
|
Onglyza
|
63
|
(8)
|
(3)
|
14
|
(26)
|
37
|
9
|
17
|
9
|
(17)
|
(17)
|
3
|
(32)
|
(17)
|
|
Bydureon
|
45
|
(33)
|
(32)
|
38
|
(32)
|
1
|
44
|
45
|
7
|
(38)
|
(34)
|
(1)
|
n/m
|
n/m
|
|
Others
|
102
|
4
|
9
|
5
|
(25)
|
61
|
19
|
27
|
35
|
(5)
|
(4)
|
1
|
(63)
|
(59)
|
|
BioPharmaceuticals: R&I
|
1,583
|
5
|
10
|
617
|
(4)
|
533
|
22
|
31
|
292
|
5
|
11
|
141
|
(6)
|
3
|
|
Symbicort
|
688
|
2
|
7
|
233
|
(10)
|
229
|
37
|
48
|
147
|
(6)
|
(1)
|
79
|
(14)
|
(7)
|
|
Fasenra
|
338
|
10
|
13
|
201
|
6
|
14
|
n/m
|
n/m
|
88
|
17
|
23
|
35
|
(4)
|
7
|
|
Breztri
|
144
|
67
|
73
|
81
|
53
|
38
|
71
|
85
|
15
|
n/m
|
n/m
|
10
|
52
|
73
|
|
Saphnelo
|
47
|
n/m
|
n/m
|
44
|
n/m
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
|
Tezspire
|
11
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
7
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
|
Pulmicort
|
221
|
2
|
9
|
10
|
(54)
|
182
|
11
|
19
|
20
|
12
|
19
|
9
|
(31)
|
(25)
|
|
Bevespi
|
15
|
(1)
|
2
|
9
|
(15)
|
2
|
9
|
21
|
4
|
55
|
64
|
-
|
-
|
-
|
|
Daliresp/Daxas
|
13
|
(75)
|
(75)
|
9
|
(80)
|
1
|
(19)
|
(17)
|
2
|
(6)
|
(2)
|
1
|
35
|
(36)
|
|
Others
|
106
|
(27)
|
(22)
|
30
|
(44)
|
67
|
(9)
|
(1)
|
8
|
(54)
|
(50)
|
1
|
(12)
|
(7)
|
|
BioPharmaceuticals: V&I
|
355
|
(80)
|
(78)
|
-
|
n/m
|
104
|
(84)
|
(83)
|
98
|
(66)
|
(64)
|
153
|
(66)
|
(62)
|
|
COVID-19 mAbs
|
127
|
(73)
|
(70)
|
-
|
n/m
|
8
|
(91)
|
(91)
|
4
|
(94)
|
(93)
|
115
|
n/m
|
n/m
|
|
Vaxzevria
|
28
|
(97)
|
(97)
|
-
|
n/m
|
18
|
(96)
|
(96)
|
10
|
(93)
|
(92)
|
-
|
n/m
|
n/m
|
|
Synagis
|
198
|
(1)
|
5
|
-
|
-
|
78
|
17
|
21
|
82
|
(5)
|
-
|
38
|
(18)
|
(7)
|
|
FluMist
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Rare Disease
|
1,866
|
10
|
14
|
1,094
|
7
|
173
|
51
|
57
|
387
|
7
|
14
|
212
|
7
|
21
|
|
Soliris
|
834
|
(16)
|
(13)
|
448
|
(24)
|
115
|
63
|
77
|
183
|
(17)
|
(12)
|
88
|
(18)
|
(10)
|
|
Ultomiris
|
651
|
55
|
61
|
381
|
73
|
13
|
(46)
|
(45)
|
159
|
52
|
61
|
98
|
39
|
61
|
|
Strensiq
|
262
|
26
|
28
|
205
|
28
|
15
|
70
|
58
|
21
|
10
|
17
|
21
|
7
|
22
|
|
Koselugo
|
79
|
n/m
|
n/m
|
41
|
34
|
24
|
n/m
|
n/m
|
11
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
|
Kanuma
|
40
|
4
|
6
|
19
|
3
|
6
|
(1)
|
(6)
|
13
|
5
|
10
|
2
|
31
|
44
|
|
Other medicines
|
312
|
(26)
|
(21)
|
36
|
(8)
|
205
|
-
|
8
|
22
|
(38)
|
(37)
|
49
|
(66)
|
(62)
|
|
Nexium
|
244
|
(27)
|
(20)
|
29
|
(12)
|
156
|
8
|
17
|
12
|
(19)
|
(15)
|
47
|
(67)
|
(62)
|
|
Others
|
68
|
(26)
|
(23)
|
7
|
19
|
49
|
(18)
|
(13)
|
10
|
(52)
|
(52)
|
2
|
(63)
|
(58)
|
|
Total Product Sales
|
10,566
|
(4)
|
1
|
4,073
|
2
|
3,146
|
(5)
|
2
|
2,116
|
1
|
7
|
1,231
|
(23)
|
(13)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2023
|
Q1 2022
|
|
|
$m
|
$m
|
Enhertu
|
|
220
|
76
|
Tezspire
|
|
43
|
3
|
Vaxzevria: royalties
|
|
-
|
56
|
Other royalty income
|
|
20
|
16
|
Other Alliance Revenue
|
|
3
|
1
|
Total
|
|
286
|
152
|
|
|
Q1 2023
|
Q1 2022
|
|
|
$m
|
$m
|
Lynparza: regulatory
milestones
|
|
-
|
175
|
Farxiga: sales
milestones
|
|
24
|
-
|
tralokinumab: sales milestones
|
|
-
|
70
|
Other Collaboration Revenue
|
|
3
|
13
|
Total
|
|
27
|
258
|
|
|
Q1 2023
|
Q1 2022
|
|
|
$m
|
$m
|
brazikumab licence termination funding
|
|
38
|
35
|
Divestment of US rights to Pulmicort Flexhaler
|
|
241
|
-
|
Other
|
|
100
|
62
|
Total
|
|
379
|
97
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
db@astfinancial.com
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions